{"organizations": [], "uuid": "25da2d29099c9d9952e4f36b1d17b2d38e42aad3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180206.html", "section_title": "Archive News &amp; Video for Tuesday, 06 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-cspc-pharmaceutical-groups-gastric/brief-cspc-pharmaceutical-groups-gastric-cancer-drug-granted-orphan-drug-designation-by-u-s-fda-idUSFWN1PW0HO", "country": "US", "domain_rank": 408, "title": "BRIEF-CSPC Pharmaceutical Group's Gastric Cancer Drug Granted Orphan-Drug Designation By U.S. FDA​", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.621, "site_type": "news", "published": "2018-02-06T18:29:00.000+02:00", "replies_count": 0, "uuid": "25da2d29099c9d9952e4f36b1d17b2d38e42aad3"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-cspc-pharmaceutical-groups-gastric/brief-cspc-pharmaceutical-groups-gastric-cancer-drug-granted-orphan-drug-designation-by-u-s-fda-idUSFWN1PW0HO", "ord_in_thread": 0, "title": "BRIEF-CSPC Pharmaceutical Group's Gastric Cancer Drug Granted Orphan-Drug Designation By U.S. FDA​", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "cspc pharmaceutical group ltd", "sentiment": "negative"}, {"name": "brief-cspc pharmaceutical group", "sentiment": "negative"}, {"name": "u.s. fda", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 6 (Reuters) - CSPC Pharmaceutical Group Ltd:\n* ‍GROUP‘S GASTRIC CANCER DRUG “DP303C” WAS GRANTED ORPHAN-DRUG DESIGNATION BY U.S. FDA​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-06T18:29:00.000+02:00", "crawled": "2018-02-07T21:53:03.029+02:00", "highlightTitle": ""}